for HD Chorea in Adults

ABOUT THE CLINICAL STUDY

A clinical study measured the effects of AUSTEDO in people
with Huntington’s disease (HD) chorea1*

FIRST GOAL OF THE STUDY1,2

To measure the effectiveness of AUSTEDO on:

  • HD chorea symptoms using the Total Maximal
    Chorea (TMC) score
  • TMC score progress before, during, and at the
    end of the 12-week study

SECOND GOAL OF THE STUDY1,2

To evaluate the effects of AUSTEDO on:

  • Overall HD symptoms, as reported
    by people and their doctors
  • Limitations on people’s ability to
    perform daily activities

About the study1:

90 people with HD chorea were studied for 12 weeks.

45 people were selected to take AUSTEDO (deutetrabenazine) tablets and 45 people were
selected to take placebo (inactive tablets).

Involuntary movements were measured at the beginning and end of the study, with movements
also being observed at intervals throughout the 12-week period.*

*Once-daily AUSTEDO XR contains the same active ingredient as twice-daily AUSTEDO. Data on this page is based on twice-daily dosing.1

Sex2

Pie chart showing 55.6% male participants and 44.4% female participants in AUSTEDO clinical study.

FEMALE

44.4%

MALE

55.6%

Medications people taking AUSTEDO were able
to continue throughout the trial2

62.2 percent of people taking Austedo® also took antidepressants. 35.5 percent also take antiepileptics. 15.5 percent take antianxiety medications.

ANTIDEPRESSANTS

62.2%

Antiepileptics

35.5%

Antianxiety
medications

15.5%

Stay in the know

Sign up for HD chorea treatment tips, information
about patient support, and educational resources.

References:

1. AUSTEDO® XR (deutetrabenazine) extended-release tablets/AUSTEDO® tablets current Prescribing Information. Parsippany, NJ: Teva Neuroscience, Inc.

2. Data on file. Parsippany, NJ: Teva Neuroscience, Inc.

3. Frank S, Stamler D, Kayson E, et al; Huntington Study Group/Alternatives for Reducing Chorea in Huntington Disease Investigators. Safety of converting from tetrabenazine to deutetrabenazine for the treatment of chorea. JAMA Neurol. 2017;74(8):977‐982.